ONTX News and Press, Onconova Therapeutics Inc. From 05/11/22

Onconova Therapuetics (NASDAQ:ONTX) saw its Q1 2022 net loss narrow ~13% year-over-year to ~4.1M (-$0.20 per share, basic and diluted) even as revenue was unchanged. Revenue in the quarter was $56K. The cancer therapy company missed on the top and bottom lines. Operating expenses were also fl...

The following slide deck was published by Onconova Therapeutics, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Onconova Therapeutics, Inc. 2022 Q1 - Results - Earnings Call Presentation

Onconova Therapeutics press release (NASDAQ:ONTX): Q1 GAAP EPS of -$0.20 misses by $0.01. Revenue of $0.06M (flat Y/Y) misses by $0.02M. For further details see: Onconova Therapeutics GAAP EPS of -$0.20 misses by $0.01, revenue of $0.06M misses by $0.02M

NEWTOWN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three mo...

ACOR, ADMA, APP, ASM, ASND, ASYS, ATCO, BAK, BMBL, BROS, BYND, CLPT, CLSD, CPA, CPNG, CYCC, DIS, DOX, ENVX, FLNC, FOSL, FSM, GAIN, GBDC, ICAD, KGC, LGO, LKCO, LTBR, MBII, METC, MFC, MQ, MRAM, MYO, NEON, NOAH, OCX, ONTX, OR, OTRK, PAAS, PAYS, PSTL, OTCPK:PWCDF, RIVN, SAND, SCM, SCTL, SLF, SMTS...

NEWTOWN, Pa., May 04, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to releas...

NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced the acceptance of an abstract for publication at the America...

Onconova Presented Data At The Next Generation Kinase Inhibitors Summit. Onconova presented data from narazaciclib studies at an industry meeting attended by academic and corporate scientists. New data is not presented at this type of meeting, but speakers are able to present more information ...

NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate...

Onconova Reported FY2021 and Updated Its Clinical Trials In Progress. Onconova reported a loss of $16.2 million or $(0.96) per share for FY2021. Importantly, the company reiterated its development schedule for the announcement of clinical data and the start of new clinical trials. Cash on hand...